Active, not recruiting
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
NCT05469009
- Conditions
- Alzheimer Disease 1, Alzheimer disease type 1, Cognition Disorders, +4 more
- Locations
-
- West Virginia University Rockefeller Neuroscience Institute Morgantown, West Virginia, United States